hCCR8(2)
Nomenclature
C57BL/6Smoc-Ccr8em3(hCCR8)/Smoc
Cat. NO.
NM-HU-2000054
Strain State
Repository Live
Gene Summary
Gene Symbol
CCR8
Model Description
Validation Data
Fig1. Expression characterization of CCR8 humanized mouse.
(A) Human CCR8 expression on activated splenic CD4+, CD8+ and Treg cells upon anti-mCD3/mCD28 stimulation in hCCR8 mice; (B) Statistics of T cell populations in hCCR8 mice.
Fig2. The anti-hCCR8 therapeutic antibody shows potent antitumor efficacy in hCCR8 mice.
(A) and (B) in vivo antitumor response of anti-hCCR8 in hCCR8 mice bearing MC38 tumor.
Fig3. In vivo antitumor responses of anti-hCCR8 alone or in combination with anti-PD-1 in hCCR8 knockin mice engrafted with MC38 tumor.
(A) Mean tumor growth curves upon treatment; (B) Individual tumor growth curves upon treatment.
Fig4. In vivo efficacy study in CCR8 humanized mice grafted with MC38 tumor model. JTX-1811 can inhibit the growth of MC38 xenografts (A) without significant effect on the body weight of CCR8 humanized mice (B).(provided by partner)
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
